Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
galantamine
- Development stage
- Approved
- Lead developer
- Johnson & Johnson
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Galantamine is a small molecule acetylcholinesterase inhibitor used primarily for the treatment of mild to moderate dementia associated with Alzheimer's disease. It acts as a competitive and reversible inhibitor of acetylcholinesterase, thereby increasing levels of acetylcholine in the brain and enhancing cholinergic neurotransmission. In addition to its anticholinesterase activity, galantamine is also a positive allosteric modulator of neuronal nicotinic acetylcholine receptors. This dual mechanism may contribute to improvements in cognition, global function, activities of daily living, and behavioral symptoms in patients with Alzheimer's disease. Galantamine does not cure or halt the progression of Alzheimer's disease but can provide symptomatic relief for some patients[1][2][3][6]. Developed by Janssen.
- Brand names
- RazadyneRazadyne ERReminyl
- Other names
- galantamine hydrobromide extended-releasegalantamine ER
02
Targets
Nicotinic Acetylcholine ReceptorAcetylcholinesterase
Beyond the preview
Go deeper on galantamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on galantamine.